A recent consensus & expert recommendations published in the Primary Care Respiratory Medicine journal has revealed ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

Altesa BioSciences, Inc., a clinical-stage pharmaceutical company developing new treatments for viral infections in vulnerable populations, today announced the appointment of Katharine Knobil, M.D. as ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

More people may be at risk for developing COPD due to exposure to environmental irritants, such as heat waves and air pollution. Pulmonologists weigh in on whether climate change could mean more ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

A new study published in the journal of BMC Pulmonary Medicine showed that dyspnea (mMRC score 1.67), symptom load (CAT score ...

Climate change is affecting the health of all individuals and represents an even more significant health risk for individuals with COPD.

In our study, β-blocker use was not associated with a difference in all-cause hospitalizations ... potentially limiting the number of COPD exacerbations that were captured.

Among older adults with established ASCVD, hospitalization for COPD increases risk of ASCVD hospitalization. The risk for atherosclerotic cardiovascular disease (ASCVD) hospitalization after ...